BioOutsource Opens New Facility in Cambridge, Massachusetts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BioOutsource Opens New Facility in Cambridge, Massachusetts



BioOutsource, a contract testing services provider to the biopharmaceutical industry, has opened a new facility in Cambridge, Massachusetts. The facility marks the company's first North American offices, which were opened in response to increasing demand for the company's bioanalytical and biosafety services, particularly in the field of biologic and biosimilar characterisation. The announcement was made at the 2013 BIO International Convention, "the Global Event for Biotechnology," in Chicago, Illinois.

BioOutsource stated in the company’s press release that it will draw on its experience in providing biosimilar characterisation assays to its European customers, in providing similar services throughout North America. The office will be located at the Cambridge Innovation Center on Kendall Square, which is adjacent to the Massachusetts Institute of Technology campus and home to a number of growing life sciences and venture capital firms.

Gerry MacKay, CEO of BioOutsource said that the new facility "will facilitate engagement with North American customers for our off-the-shelf biosimilar biological characterisation assays, for example for Humira, Enbrel, Rituxan, Herceptin, Remicade, and Avastin."

"We are in the fortunate position to have been first-to-market in both Europe and the US with our assays, and count Big Pharma as well as leading biotechnology as valued customers," said Verna McErlane, BioOutsource director of sales and business development, bioanalytical division. “We look forward to being able to interact with them and provide our market-leading services, that much more readily, from our North American base of operations in Cambridge. Cambridge is, of course, part of greater Boston, which is now the number one cluster for early-stage biotechnology, and a growing center of operations for some of the world's leading pharmaceutical firms, as well."

"We see the North American market as an essential strategic element of our global expansion plans. We remain committed to not only growing our business in North America but in nurturing our relationships with our existing North American clients, as well. We invite all our customers and potential customers to stop by our new offices whenever you are in the Boston area," MacKay concluded.

BioOutsource provides contract testing services to the biopharmaceutical industry. Core offerings include a range of services to support the testing of biologics, vaccines and biosimilars throughout their development.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here